Advertisement

Epilepsy and Behavior: Response to an Integrative Treatment Paradigm Highlighting Complementary and Alternative Medicine

  • V. Misra
  • V. G. Srivatsa
  • E. S. Krishnamoorthy
Chapter

Abstract

Epilepsy is a complex disorder which requires multidisciplinary management. Comorbidities such as anxiety and depression, intellectual disability, and comorbid neuropsychiatric disorders are common. In severe cases, particularly when modalities such as surgical intervention are not feasible, an individual may have to live with recurring seizures. Such challenges can result in exacerbation of psychosocial stressors and emotional and behavioral problems. In these instances, complementary and alternative medicine (CAM) approaches along with a well-integrated psychotherapeutic and medical model may provide significant functional improvement. This is the case of a young man who has struggled with nearly lifelong epilepsy that is medically refractory. He engaged in a detailed evaluation informed by pharmacogenetics studies and improved with a novel multimodal treatment paradigm.

Keywords

Epilepsy Anxiety Complementary alternative medicine CAMS Yoga Ayurveda 

References

  1. 1.
    Piña-Garza JE. Chapter 1 – Paroxysmal disorders. In: Fenichel’s clinical pediatric neurology [Internet]. 7th ed. London: W.B. Saunders; 2013. p. 1–46.Google Scholar
  2. 2.
    Marrus N, Hall L. Intellectual disability and language disorder. Child Adolesc Psychiatr Clin N Am. 2017;26(3):539–54.CrossRefGoogle Scholar
  3. 3.
    Espie C, Watkins J, Curtice L, Espie A, Duncan R, Ryan J, et al. Psychopathology in people with epilepsy and intellectual disability; an investigation of potential explanatory variables. J Neurol Neurosurg Psychiatry. 2003;74(11):1485–92.CrossRefGoogle Scholar
  4. 4.
    Glauser TA, Holland K, O’Brien VP, Keddache M, Martin LJ, Clark PO, Cnaan A, Dlugos D, Hirtz DG, Shinnar S, Grabowski G. Pharmacogenetics of antiepileptic drug efficacy in childhood absence epilepsy. Ann Neurol. 2017;81(3):444–53.CrossRefGoogle Scholar
  5. 5.
    Balestrini S, Sisodiya SM. Pharmacogenomics in epilepsy. Neurosci Lett. 2017;667:27–39.CrossRefGoogle Scholar
  6. 6.
    Franco V, Perucca E. The pharmacogenomics of epilepsy. Expert Rev Neurother. 2015;15(10):1161–70.CrossRefGoogle Scholar
  7. 7.
    McCormack M, Alfirevic A, Bourgeois S, Farrell JJ, Kasperavičiūtė D, Carrington M, Sills GJ, Marson T, Jia X, de Bakker PI, Chinthapalli K. HLA-A* 3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med. 2011;364(12):1134–43.CrossRefGoogle Scholar
  8. 8.
    Hogarty G, Greenwald DP. Cognitive enhancement therapy: the training manual [Internet]. University of Pittsburgh Medical Center; 2006. Available from: www.CognitiveEnhancementTherapy.com.

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • V. Misra
    • 1
  • V. G. Srivatsa
    • 1
  • E. S. Krishnamoorthy
    • 1
  1. 1.NeurokrishChennaiIndia

Personalised recommendations